Pharming Analyst Price Targets - Benzinga

Pharming Group

PHARNASDAQ

Trade with Public

Trade with Public

$9.99

-0.02-0.2%

Últ. Act.: Sep 29, 8:26 AM

$10.20

0.191.9%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Comparar Informe de acciones

Pharming Analyst Price Targets - Benzinga

Pharming Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pharming (PHAR).

Price Target Range — 8 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$34Upside to Avg. PT+231.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 22, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Sep 14, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Aug 3, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$37→$38
Apr 10, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$37
Mar 24, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Mar 13, 2026	Oppenheimer	Jeff Jones	PT Cut	Outperform	$42→$41
Mar 21, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Mar 20, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Mar 14, 2025	Oppenheimer	Michael Carrier	PT Raise	Outperform	$30→$39
Mar 14, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Dec 17, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Dec 16, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Dec 11, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Dec 9, 2024	Jefferies	Lucy Codrington	Initiate	Buy	$14
Oct 28, 2024	Oppenheimer	Michael Carrier	PT Cut	Outperform	$31→$30
Oct 24, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Oct 15, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Oct 10, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Sep 26, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Aug 1, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $38

Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $37 to $38.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Pharming with Buy Rating, Announces Price Target of $37

Canaccord Genuity analyst Whitney Ijem initiates coverage on Pharming (NASDAQ:PHAR) with a Buy rating and announces Price Target of $37.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Pharming, Lowers Price Target to $41

Oppenheimer analyst Jeff Jones reiterates Pharming (NASDAQ:PHAR) with a Outperform and lowers the price target from $42 to $41.

Benzinga Newsdesk